Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Operating Expenses: 2016-2024

Historic Other Operating Expenses for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Dec 2024 value amounting to $76.7 million.

  • Ultragenyx Pharmaceutical's Other Operating Expenses rose 33.16% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.5 million, marking a year-over-year increase of 34.31%. This contributed to the annual value of $76.7 million for FY2024, which is 69.72% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Other Operating Expenses of $76.7 million as of FY2024, which was up 69.72% from $45.2 million recorded in FY2023.
  • Ultragenyx Pharmaceutical's Other Operating Expenses' 5-year high stood at $76.7 million during FY2024, with a 5-year trough of $6.1 million in FY2020.
  • Moreover, its 3-year median value for Other Operating Expenses was $45.2 million (2023), whereas its average is $50.1 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first crashed by 31.96% in 2020, then surged by 161.18% in 2021.
  • Yearly analysis of 5 years shows Ultragenyx Pharmaceutical's Other Operating Expenses stood at $6.1 million in 2020, then spiked by 161.18% to $16.0 million in 2021, then spiked by 76.91% to $28.3 million in 2022, then skyrocketed by 59.64% to $45.2 million in 2023, then skyrocketed by 69.72% to $76.7 million in 2024.